Scholars Central

Conference abstractPublished 20 Jul 2015

AMP-activated protein kinase inhibitor compound C inhibits adipocyte conditioned medium-induced macrophage chemotaxis and inflammation through targeting focal adhesion kinase and IκB kinase

Authors: Seong Ji Woo, Youngyi Lee, Eun Ju Bae, Byung-Hyun Park

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Macrophage infiltration and inflammation in adipose tissue are well established to cause obesity-linked insulin resistance and type 2 diabetes. AMP-activated protein kinase (AMPK) has pleiotropic effects for energy metabolism, but its role for adipocyte-promoted macrophage chemotaxis has not been explored. Here, we report that an AMPK inhibitor, compound C (CC), significantly inhibited adipocyte conditioned medium (CM)-induced macrophage chemotaxis in RAW 264.7 cells in a concentration dependent manner, and this inhibitory effect was accompanied by the inhibition of focal adhesion kinase (FAK), AKT and inhibitory κB kinase (IKK) in macrophages, which all are important regulators of cell migration. Inhibition of macrophage chemotaxis by CC was not prevented but potentiated by co-treatment with AMPK activator 5-aminoimidazole-4- carboxamide ribonucleotide (AICAR), indicating that CC inhibition of AMPK is not involved in its suppression of chemotaxis. Instead, FAK phosphorylation was additively reduced by combined treatment of CC and AICAR, suggesting that CC and AICAR prevent adipocyte macrophage chemotaxis through targeting FAK pathway. CC treatment also prevented the expression of proinflammatory genes in RAW 264.7 macrophages when stimulated with either CM or lipopolysaccharide (LPS) and this effect was mediated by inhibition of IKK/NFκB pathway. Lastly, we demonstrated that CC functioned as a repressor of macrophagemediated insulin resistance in adipocytes. Our results suggest that CC might serve as a useful molecule in research on adipocytemediated macrophage chemotaxis and as a potential lead compound for the treatment of obesity-linked insulin resistance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical and Cellular Immunology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Seong Ji Woo”
  • BylineArticles whose byline prints “Youngyi Lee”
  • BylineArticles whose byline prints “Eun Ju Bae”
  • BylineArticles whose byline prints “Byung-Hyun Park”